Positive Biomarker Results from PROTECT Trial

AI SummaryClose X

Allergy Therapeutics PLC announced positive biomarker results from its PROTECT Phase I/IIa trial for VLP Peanut, demonstrating a strong immunomodulating response in peanut-allergic subjects. The trial showed significant reductions in basophil sensitivity and IgE-Fab binding to the main allergen Ara h2, with the highest dose reaching statistical significance. Furthermore, a dose-dependent increase in Ara h2-specific IgG was observed, and a reduction in wheal diameter after skin prick testing was noted. These findings, coupled with a supportive safety profile, suggest VLP Peanut has transformational clinical potential as a short-course treatment option.

Disclaimer*

UK 100

Latest directors dealings